Diagnostic Criteria for Acute Kidney Injury (AKI)
AKI is diagnosed when any one of the following KDIGO criteria is met: serum creatinine rises ≥0.3 mg/dl (≥26 μmol/l) within 48 hours, OR serum creatinine increases to ≥1.5 times baseline within 7 days, OR urine output falls below 0.5 ml/kg/h for more than 6 hours. 1
Initial Detection Criteria
Meeting any single criterion from Stage 1 establishes the diagnosis of AKI:
Serum Creatinine Criteria
- Absolute rise: ≥0.3 mg/dl (≥26 μmol/l) within 48 hours
- Relative rise: ≥50% (1.5-fold) increase from baseline within 7 days
Urine Output Criterion
- <0.5 ml/kg/h for more than 6 consecutive hours
The KDIGO criteria represent a merger of the earlier RIFLE and AKIN classifications, designed to maximize sensitivity for detecting AKI while maintaining prognostic validity. Notably, even small creatinine rises of ≥0.3 mg/dl are independently associated with approximately fourfold increased hospital mortality 1.
Severity Staging
Once AKI is detected, severity is staged retrospectively based on the highest stage reached by either creatinine or urine output criteria:
Stage 1
- Creatinine: Rise ≥0.3 mg/dl within 48h OR 1.5-1.99× baseline within 7 days
- Urine output: <0.5 ml/kg/h for >6 hours
Stage 2
- Creatinine: 2.0-2.99× baseline within 7 days
- Urine output: <0.5 ml/kg/h for >12 hours
Stage 3
- Creatinine: ≥3.0× baseline within 7 days OR creatinine ≥354 μmol/l (4.0 mg/dl) with documented acute rise OR initiation of renal replacement therapy
- Urine output: <0.3 ml/kg/h for 24 hours OR anuria for 12 hours
Critical Implementation Points
Baseline Creatinine Determination
When baseline creatinine is unknown, estimate it by back-calculating from an assumed GFR of 75 ml/min/1.73m² using the MDRD equation 2. This approach reliably predicts RIFLE stages I and F.
Common Pitfalls to Avoid
Volume status confounding: Serum creatinine is a concentration, not an absolute value. Massive fluid resuscitation can dilute creatinine, masking true GFR decline. A patient may have significant kidney injury but fail to meet absolute creatinine rise criteria due to volume expansion. The combined KDIGO criteria (absolute + relative rise) partially addresses this by capturing cases missed by single criteria 2.
Timing windows matter: The 48-hour window for absolute rise (≥0.3 mg/dl) differs from the 7-day window for relative rise (≥50%). Both must be actively monitored—a patient may meet one criterion but not the other 1.
Urine output measurement: Oliguria criteria require accurate hourly urine measurement with indwelling catheter. Without reliable urine quantification, diagnosis relies solely on creatinine criteria 1.
Chronic kidney disease patients: In CKD patients, any rise to creatinine ≥354 μmol/l (4.0 mg/dl) with documented acute change qualifies as Stage 3 AKI, whereas the same absolute value in non-CKD patients may only represent Stage 1 1.
Validation and Outcomes
The KDIGO criteria have been extensively validated across multiple studies. Patients meeting AKI criteria by either creatinine or urine output demonstrate significantly increased mortality compared to non-AKI patients (27-32% vs 5-7%, P<0.001) 3. Patients manifesting both oliguria and azotemia have worse outcomes than those meeting single criteria, emphasizing the importance of monitoring both parameters 4.
KDIGO identifies more AKI cases than AKIN (51% vs 38.4%, P<0.001) and demonstrates superior predictive ability for in-hospital mortality compared to RIFLE criteria 3.
Determining Etiology
Once AKI is diagnosed, the underlying cause must be identified through systematic evaluation of prerenal (volume depletion, hypotension), intrarenal (acute tubular necrosis, glomerulonephritis, interstitial nephritis), and postrenal (obstruction) etiologies 2, 5. This classification guides specific management beyond supportive care.